Shen A, Arbesman M, Lodha R, Rayman P, et al. Germline Pathogenic Variant (gPV) Positive Patients with Melanoma Exhibit Improved Response to Checkpoint Inhibitor Immunotherapy. J Invest Dermatol 2025 Jan 13:S0022-202X(25)00004.
PMID: 39814198